Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes-Reference-Cited by-同舟云学术

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes

Published:2016-05-26 Issue:9 Volume:18 Page:868-874
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Allas S.¹,Delale T.¹,Ngo N.²,Julien M.¹,Sahakian P.¹,Ritter J.³,Abribat T.¹,van der Lely A. J.⁴

Affiliation:

1. Alizé Pharma; Ecully France

2. Quintiles Early Clinical Development PK Department; Overland Park KS USA

3. Phase 1 Quintiles Unit; London UK

4. Department of Medicine; Erasmus University Medical Centre; Rotterdam The Netherlands

Funder

Alizé Pharma

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12675/fullpdf

Reference24 articles.

1. Ghrelin is a growth-hormone-releasing acylated peptide from stomach;Kojima;Nature,1999

2. Ghrelin octanoylation mediated by an orphan lipid transferase;Gutierrez;Proc Natl Acad Sci U S A,2008

3. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone;Yang;Cell,2008

4. Effect of des-acyl ghrelin on adiposity and glucose metabolism;Zhang;Endocrinology,2008

5. Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice;Delhanty;PLoS One,2010

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease;Current Pharmaceutical Design;2023-09-06

2. Desacyl-ghrelin, not just an inactive form of ghrelin? A review of current knowledge on the biological actions of desacyl-ghrelin;Peptides;2023-09

3. Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies;Metabolism;2023-06

4. Feeding-induced hepatokines and crosstalk with multi-organ: A novel therapeutic target for Type 2 diabetes;Frontiers in Endocrinology;2023-03-03

5. Novel therapies with precision mechanisms for type 2 diabetes mellitus;Nature Reviews Endocrinology;2021-05-04